Fecal Microbiota Transplantation for Recurrent Clostridium difficile InfectionBrandt, Lawrence J. MD*,†; Reddy, Sheela S. MD†Journal of Clinical Gastroenterology: November/December 2011 - Volume 45 - Issue - p S159–S167 doi: 10.1097/MCG.0b013e318222e603 PRESENTATIONS Abstract Author InformationAuthors Article MetricsMetrics With the increasing prevalence of recurrent/refractory Clostridium difficile infection (CDI), alternative treatments to the standard antibiotic therapies are being sought. One of the more controversial of such alternative treatments is fecal microbiota transplantation (FMT). Although the notion of FMT is foreign—even startling—and not esthetic to most people, the concept has been around for many decades. Its benefit and efficacy dates back >50 years to its use for staphylococcal pseudomembranous colitis, and now FMT is showing a great promise as an inexpensive, safe, and highly efficient treatment for recurrent and refractory CDI. Moreover, with a better understanding of the intricacies of the colonic microbiome and its role in colonic pathophysiology, FMT has the potential to become the standard of care for CDI treatment, and a potential answer to other intestinal disorders in years to come. *Moses Division of Montefiore Medical Center, Albert Einstein College of Medicine †Division of Gastroenterology, Department of Medicine, Bronx, NY Reprints: Lawrence J. Brandt, MD, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467 (e-mail: Lbrandt@montefiore.org). Lawrence J. Brandt, M.D is consultant for Optimer Pharmaceuticals, Inc. Sheela S. Reddy, M.D declares no conflicts of interest. © 2011 Lippincott Williams & Wilkins, Inc.